WO2024188443 - MARKER TO PREDICT RESPONSE TO TREATMENT OF INFLAMMATORY BOWEL DISEASE
National phase entry is expected:
Publication Number
WO/2024/188443
Publication Date
19.09.2024
International Application No.
PCT/EP2023/056321
International Filing Date
13.03.2023
Title **
[English]
MARKER TO PREDICT RESPONSE TO TREATMENT OF INFLAMMATORY BOWEL DISEASE
[French]
MARQUEUR POUR PRÉDIRE LA RÉPONSE AU TRAITEMENT D'UNE MALADIE INFLAMMATOIRE DE L'INTESTIN
Applicants **
UNIVERSITEIT GENT
Inventors
LAUKENS, Debby
DE GALAN, Cara
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1807 | |
| EPO | Filing, Examination, Granting | 8126 | |
| Japan | Filing, Examination, Granting | 1908 | |
| South Korea | Filing, Examination, Granting | 1477 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
18,058
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to the field of markers to predict the response of treatment of disease. Indeed, the present invention discloses that the amounts of a specific subset of NK cells –i.e. HLADR+CD56dimCD16+ NK cells- in blood samples taken from inflammatory bowel disease (IBD) patients who do not respond to treatment with a biologic medicine are significantly higher than the amounts which are found in responders to the same treatment. Hence the present invention relates to usages of said specific subset of natural killer (NK) cells to predict the (lack of) response by IBD patients to treatment with biologic medicines and/or to methods to predict the (lack of) response of said treatment.[French]
La présente invention se rapport au domaine des marqueurs pour prédire la réponse au traitement d'une maladie. En effet, la présente invention divulgue que les quantités d'un sous-ensemble spécifique de cellules NK – c'est-à-dire des cellules NK HLADR+CD56dimCD16+ – dans des échantillons de sang prélevés sur des patients atteints de maladie inflammatoire de l'intestin (IBD) qui ne répondent pas au traitement avec un médicament biologique sont significativement supérieures aux quantités qui sont trouvées chez les patients qui répondent au même traitement. Par conséquent, la présente invention concerne des utilisations dudit sous-ensemble spécifique de cellules tueuses naturelles (NK) pour prédire la (le manque de) réponse par des patients atteints d'IBD à un traitement avec des médicaments biologiques et/ou à des procédés pour prédire la (le manque de) réponse audit traitement.